Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT00101595 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia
Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Interventions

DRUG: Dasatinib

Sponsor

Bristol-Myers Squibb